Precigen, Inc. · NASDAQ:PGEN
Precigen — Q2 2020 Earnings Presentation
13 slides from Precigen's earnings presentation, Aug 10, 2020
Slide 1: Precigen, Inc. 2Q-2020 Business Update
Exhibit 99.2 Precigen, Inc. 2Q-2020 Business Update 10 August 2020 1Exhibit 99.2 Precigen, Inc. 2Q-2020 Business Update 10 August 2020 1
Slide 2: Forward-looking Statements
Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projecti
Slide 3: Q2 2020 Financial Highlights
Q2 2020 Financial Highlights Improvement in quarter over quarter Segment Adjusted EBITDA Reduction in capital requirements driven by suspension of MBP Titan operations and streamlining corporate functions Trans Ova Genetics and Precigen Exemplar cash flow positive in H1 2020 Current cash on hand suf
Slide 4: Goal: a commercially viable UltraCAR-T platform
Precigen’s goal is to develop a commercially viable UltraCAR-T platform Scale-up q Minimal handling of cells during production q Rapid and efficient gene transfer q Process a large number of T cells Manufacturing q Consistent manufacturing across various sites þ Overnight manufacturing at medical ce
Slide 5: Today's electroporation devices have scale-up limitations
Today’s electroporation devices have scale-up limitations § Relatively low throughput § Processing of one cuvette at a time § Labor and time intensive process § Multiple batches needed for manufacturing a dose § Manual handling may increase contamination risk 5Today’s electroporation devices have sc
Slide 6: UltraPorator designed to commercially scale-up UltraCAR-T manufacturing
™ UltraPorator is designed to commercially scale-up UltraCAR-T manufacturing § Precigen’s proprietary system § Electroporation optimized for UltraCAR-T § Semi-closed system minimizes manual handling § Rapid, high efficiency gene transfer protocol § High throughput system handles a large number of T
Slide 7: PRGN-3005 UltraCAR-T in ovarian cancer
® PRGN-3005 UltraCAR-T , a first-in-class therapy in ovarian cancer § Phase 1 trial is ongoing § Arm A: Intraperitoneal (IP) infusion; Arm B: Intravenous (IV) infusion § Enrollment in Dose Level 3 of IP arm is ongoing § 100% manufacturing success to date § Encouraging preliminary findings of UltraCA
Slide 8: PRGN-3006 UltraCAR-T in AML
® PRGN-3006 UltraCAR-T , a first-in-class therapy in AML § Phase 1/1b trial is ongoing § Arm 1: No Lymphodepletion; Arm 2: With Lymphodepletion § Enrolling patients in Arm 1 and Arm 2 concurrently § 100% manufacturing success to date § Encouraging preliminary findings of UltraCAR-T safety & kinetics
Slide 9: PRGN-2009 AdenoVerse immunotherapy for HPV-associated cancers
™ PRGN-2009, a first-in-class off-the-shelf AdenoVerse immunotherapy for HPV-associated cancers § IND to initiate Phase 1/2 trial cleared by the FDA § Phase 1 to evaluate safety and response in patients with HPV-associated cancers § Gorilla adenoviral vector, with ability for repeat injections, desi
Slide 10: PRGN-2009 multi-epitope antigen design against HPV16/18
PRGN-2009 incorporates innovative multi-epitope antigen design optimized to induce a robust immune response against HPV16/18 PRGN-2009 multi-epitope antigen design targets HPV16/18 PRGN-2009 design advantage Innovative multi-epitope antigen design Robust antigen specific immune response Broad HPV16/
Slide 11: AG019 ActoBiotics in Type 1 Diabetes
™ AG019 ActoBiotics , a first-in-class therapy in Type 1 Diabetes § Phase 1b/2a trial ongoing § Phase 1b: AG019 monotherapy; Phase 2a: AG019 in combination with teplizumab (anti-CD3 mAb) § Recent-onset T1D patients (adults and adolescent) § AG019 is a capsule formulation to express human Proinsulin
Slide 12: INXN-4001 gene therapy for heart failure
INXN-4001, a innovative gene therapy product for heart failure (HF) § Phase 1 Clinical trial Ongoing § Phase 1 enrollment complete § Triple-effector non-viral INXN-4001 is delivered via Retrograde Coronary Sinus Infusion (RCSI) § Cardiac-specific delivery to the ventricle § Interim Phase 1 data show
Slide 13: EGS
EGS x NEC SN